JNJ 90189892
Alternative Names: JNJ-90189892Latest Information Update: 19 Nov 2024
Price :
$50 *
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 18 Oct 2024 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) before October 2024
- 18 Oct 2024 Preclinical trials in Myelodysplastic syndromes in USA (unspecified route) before October 2024
- 18 Oct 2024 Janssen Research & Development plans a phase I trial for Acute myeloid leukaemia and Myelodysplastic syndromes (Second-line therapy or greater) in March 2025 (NCT06651229) (EUCT2024-514341-10-00)